The release of proteins from the intermembrane space of mitochondria is one of the pivotal events in the apoptotic process, which can lead to the activation of caspases and the ultimate demise of the cell. How these proteins exit the mitochondria is still a matter of intense debate. Here, we discuss the possible mechanisms behind the release of apoptogenic proteins, the ways in which cancer cells subvert these mechanisms, and the therapeutic regimens that aim to promote the timely loss of integrity of the outer mitochondrial membrane.
Introduction
Mammalian cells contain a sophisticated mechanism that enables them to engage in programmed cell death (apoptosis) in response to a variety of physiological, pathogenic or cytotoxic stimuli. The induction of apoptosis occurs by two distinct modes. One mode involves signalling by death receptors in the plasma membrane (extrinsic) and the other entails disruption of intracellular homeostasis (intrinsic) (Adams and Cory, 1998) . However, regardless of the mode of induction (intrinsic vs extrinsic), following the apoptotic signal a number of changes will occur within the cell. These changes have been well documented and a set of physical and biochemical hallmarks for apoptosis have been established. The biochemical hallmarks include the loss of sialic acid, fragmentation of the nuclear DNA and a translocation of phosphatidylserine to the outer plasma membrane; while physical manifestations include vacuolization, chromatin condensation, blebbing of the plasma membrane and the eventual organized disintegration of the cell into packaged 'apoptotic bodies'. In the physiological setting these discrete cellular packages are subsequently targeted and cleared by phagosomes (for a recent review see Ly et al., 2003) .
The characteristic changes associated with apoptosis are due to the activation of a family of intracellular cysteine-aspartic proteases known as caspases that often act as signal transducing molecules, connecting plasma membrane receptors to cytoplasmic events (reviewed in Earnshaw et al., 1999) . They are grouped into two categories: 'initiator' caspases (e.g. caspase-2, -8 and -9) that cleave and thereby activate various enzymes and proteins, including other caspases, and 'effector' caspases (e.g. caspase-3, -6 and -7) that degrade many cellular targets during apoptosis. Inhibition of caspases can prevent the acquisition of some of the hallmarks of apoptosis such as the formation of nuclear apoptotic bodies. While the macro changes to the cell are easily identifiable with current biochemical techniques, there is a diverse array of intercellular and intracellular signalling events, depending on the apoptotic stimulus used, that can be thought of as subroutines that promote the demise of a cell. For instance, many organelles undergo significant biochemical alterations during apoptosis, and it is now being reported that endoplasmic reticulum, the Golgi apparatus and mitochondria all contribute to apoptotic cell death (Ferri and Kroemer, 2001) .
Of all the organelles involved in apoptosis, the mitochondria have received the most attention in recent years. This is due primarily to the fact that investigators have found that after apoptotic-stimulated permeabilization of the mitochondrial outer membrane, a number of soluble proteins localized to the intermembrane space or matrix of the mitochondria translocate, and serve as caspase activators in the cytosol or stimulate endonuclease activity in the nucleus. It is this release from the mitochondria that appears to be central to most forms of apoptosis.
Known as apoptogenic proteins, these released proteins include cytochrome c (Yang et al., 1997) , AIF (Susin et al., 1996) , HtrA2/Omi (Suzuki et al., 2001) , SMAC/Diablo (Du et al., 2000) and EndoG (Li et al., 2001b; Zhang et al., 2003a) of which cytochrome c has been the most intensively studied. Upon intrinsic apoptotic stimulation, cytochrome c is released into the cytosol where it triggers the formation of the apoptosome, a multimeric molecule comprising of apoptotic protease activating factor-1 (Apaf-1), ATP or dATP and cytochrome c (Cain et al., 2002) . At present, the only known function of the apoptosome in mammalian cells is the recruitment and activation of caspase 9, a prolific initiator caspase (Hu et al., 1998; Adrain et al., 1999) . The caspase-9/apoptosome complex then targets and activates the effector caspase 3. Activation of caspase 3 is often considered as the pointof-no-return in the apoptotic signalling cascade.
The regulation of the release of apoptogenic proteins from the mitochondria is principally provided by the members of the Bcl-2 family (Korsmeyer, 1999) . The family is classified according to their function, proapoptotic or antiapoptotic, and according to the presence of domains homologous to Bcl-2 (BH domains). The antiapoptotic subset includes Bcl-2 and BclxL whose expression can override many death stimuli and block the release of cytochrome c from mitochondria. Proapoptotic family members are generally divided into two sets according to their BH domains: Bax and Bak contain 3 BH domains and are localized to the cytosol and mitochondrial membrane, respectively, and are often referred to as 'mitochondrial gatekeepers' as their deletion renders cells resistant to a wide range of apoptotic stimuli (Wei et al., 2001) . All other proapoptotic proteins of the family contain a single BH-3 domain with or without a transmembrane domain, and serve to either inactivate the antiapoptotic members (e.g. Bad) or activate Bax (and promote its insertion into the OMM) or Bak leading to the release of apoptogenic proteins. Since the overwhelming majority of cell death signals engage the mitochondrial (intrinsic) pathway, this article will review the permeabilization of the outer mitochondrial membrane (OMM) and the mechanisms of release of the soluble apoptogenic proteins and how these could relate to oncogenesis and therapeutic strategies.
The mitochondria: cellular powerhouse and much more Mitochondria are particularly affected early in the apoptotic process and are now thought to act as central coordinators of cell death (Green and Reed, 1998) . Several factors can stimulate mitochondrial-mediated apoptosis; among them, DNA damage, UV, activation of tumour suppressors, for example, p53 and oncogenes (c-Myc), chemotherapeutic agents and lipid mediators. Since many of these agents and events also cause cancer, this has led to the suggestion that the mitochondrial pathways of apoptosis have been somehow derailed in cancer cells (Shi, 2001 ). The Bcl-2 family proteins as the central regulators of the mitochondrial apoptotic pathway can either suppress or promote the changes in mitochondrial membrane permeability required for the release of cytochrome c and other apoptogenic proteins (Green and Reed, 1998; Gross et al., 1999) .
The outer mitochondrial membrane
The OMM provides a barrier under physiological conditions to prevent the release of apoptogenic proteins and contains an array of protein, lipidic and proteolipidic complexes. These include translocases of the outer membrane (TOMs) which serve to import nuclear encoded proteins into the mitochondria, adaptor proteins to link mitochondria to the cytoskeleton (Mdm (Fisk and Yaffe, 1997)), proteins for mitochondrial fission (e.g. hFis1 (James et al., 2003) ) and fusion (e.g. Mitofusin (Santel and Fuller, 2001) ), antioxidants (e.g. Tocopherol (Thomas et al., 1989) ), lipid transferases (e.g. CPT1 (Colquhoun, 1998) ), ion channels (e.g. VDAC (Colombini, 1980) ) and members of the Bcl-2 family of apoptosis regulators either as resident integral proteins (e.g. Bak) or as cytosolic translocates (Bax or tBid). One complex in particular, the mitochondrial permeability transition pore (PTP, also known as the permeability transition pore complex PTPC), first characterized by Hunter et al. (1976) is thought to play an important role in the release of proteins as the opening of a single PTP may be sufficient to release cytochrome c.
The PTP is proposed to consist of several core proteins, namely the voltage-dependent anion channel (VDAC), localized to the OMM, the adenine nucleotide translocase (ANT) in the inner mitochondrial membrane (IMM), the mitochondrial benzodiazapine receptor and cyclophilin D (Halestrap et al., 2002) . Cooperation among these proteins leads to the formation of a conductance channel which is responsible for the sudden increase in the permeability of the IMM to small molecular weight solutes and a collapse in the mitochondrial membrane potential DC m (reviewed in Ly et al., 2003) . The entry of solutes leads to a swelling of the mitochondrial matrix and a rupture of the OMM thereby releasing, in a nonspecific manner, soluble proteins from the intermembrane space. Many of the proteins released by the opening of the PTP have recently been identified by mass spectrometry and include cytochrome c (Patterson et al., 2000) . Opening of the PTP is Ca 2 þ dependent and can be inhibited by a number of agents such a cyclosporin A (CsA) which binds to cyclophilin D, Bongkrekic acid which binds to ANT, as well as Mg 2 þ , H þ , and adenine nucleotides which are thought to induce closure of the PTP by lowering the gating potential.
However, this 'classical' model of PTP opening does not appear to fit all models of membrane permeabilization during apoptosis. For example, mitochondrial swelling does not always occur and some forms of apoptosis are insensitive to CsA inhibition. Additionally, the DC m may or may not dissipate before release of proteins such cytochrome c.
The mitochondrial transmembrane potential DC m arises as a consequence of protons being pumped out of the matrix, creating a negative potential, which is utilized in the synthesis of ATP. An early loss of DC m (and therefore inhibition of ATP production by the mitochondria), has been reported in many cases of apoptotic induction (Zamzami et al., 1995; Barbu et al., 2002) . However, the decreases in DC m , are more often than not, used as a marker for mitochondrial uncoupling rather than part of a study to show its influence on permeabilization of the OMM. More recently, the kinetics of the release of cytochrome c and its relation to DC m have been studied. In some systems, a loss of DC m is required before a complete loss of cytochrome c from the mitochondria (De Giorgi et al., 2002) and reductions in DC m may be required before translocation of cytosolic proteins (Bax) to the mitochondrial membrane (Smaili et al., 2001 ) which then aids cytochrome c release.
Alternatively, there is a wealth of evidence which proposes that the release of cytochrome c can occur before or in the absence of changes in DC m (Yang et al., 1997; Gottlieb, 2000) . For example, in cerebellar granule neurons (Wigdal et al., 2002) and sympathetic neurons (Martinou et al., 1999; Deshmukh et al., 2000) cytochrome c release occurs before detectable decreases in DC m , and the addition of recombinant proapoptotic proteins to mitochondria could elicit the release of up to the 50% of the cytochrome c stores without a loss of DC m (Arnoult et al., 2003) . Further evidence from the use of mitochondrial uncouplers, FCCP and CCCP which dissipate the DC m , show that a reduction in the DC m does not induce apoptosis (Lim et al., 2001) or increase cytochrome c release (Waterhouse et al., 2002) unless ATP levels are maintained by the use of the ATPase inhibitor oligomycin (Smaili et al., 2001) . However, the mitochondrial uncouplers do profoundly affect the cytochrome c release induced by a classical Ca 2 þ -dependent PTP (Waterhouse et al., 2002) . Therefore, while cytochrome c can be released by a PTP mechanism, several of the prerequisites for the classical opening (decrease in DC m , inhibition by CsA) are missing in many current models of drug-induced cytochrome c release.
Therefore, other theories of membrane permeabilization abound (reviewed in) Desagher and Kim et al., 2003; Ly et al., 2003) and centre around the creation of a pore in the OMM by the Bcl-2 family member Bax (Saito et al., 2000) with or without the presence of other OMM proteins such as VDAC (Shimizu et al., 1999) , ANT (Marzo et al., 1998) or translocates (tBid) see below. In fact, the necessity for the members of the PTP to promote permeability of the OMM has been brought into question as studies in yeast deficient for VDAC (Pavlov et al., 2001) or ANT (Lohret et al., 1996) still undergo the permeability transition.
Bid actions at the mitochondria
With much debate surrounding the involvement of the PTP in apoptosis, and therefore possibilities of its manipulation for cancer chemotherapy, many investigators have concentrated on other potential mechanisms for generating a permeant OMM. Although a clearly defined mechanism is still lacking it is clear that Bid, a BH3-only member of the Bcl-2 family can mediate the permeabilization of the OMM in a process requiring either Bax or Bak (Wei et al., 2001) and not the PTP (Tsujimoto and Shimizu, 2000; von Ahsen et al., 2000a) .
Apoptotic signalling can lead to the cleavage of Bid (e.g. by caspase 8 or granzyme B), which generates a highly active truncated form of Bid (tBid) which localizes to the OMM. There, truncated Bid can induce the oligomerization and insertion of Bax into the OMM or the oligomerization of Bak, and subsequent release of cytochrome c (Eskes et al., 2000; Antonsson et al., 2001; Nechushtan et al., 2001; Roucou et al., 2002a; Scorrano et al., 2002) . With the involvement of the PTP effectively ruled out in this instance, the search has then continued for the mechanism behind the release of the apoptogenic proteins.
Synthetic lipid membranes used to model the OMM have provided many clues for the release. Whilst Bax oligomerization is a prerequisite of Bax-dependent cytochrome c release, pores that are created in synthetic membranes by Bax alone are not large enough to release cytochrome c (Roucou et al., 2002b) . However, such Bax oligomers can cause a mixing of the lipids and a leakage of liposomes which can be further enhanced by the addition of fatty acids (Epand et al., 2002b (Epand et al., , c, 2003 . Additionally, studies with Bid have proposed that it transports lysolipids to the OMM (Esposti et al., 2001) as well as being able to promote a negative membrane curvature of synthetic lipid membranes (Epand et al., 2002a) , and other substances that are known to create positive membrane curvature can prevent the tBidinduced membrane destabilization. Intriguingly, the PTP inhibitor cyclosporine A is one of these (see Figure 1 ).
Alterations in lipidic mixing and an accumulation of lysolipids (above basal levels) on the OMM would change the bilayer curvature and local lipid composition and thus prepare the ground for oligomerization of Bax and Bak. This could then lead to bilayer discontinuity and increased membrane permeability (Degli Esposti and Dive, 2003) . In this regard, the capacity of tBid to activate the oligomerization of Bax and Bak may be seen as a priming of the membrane lipid surface for the transmembrane pore that is subsequently produced by complexes of oligomerized proteins and specific lipids (Hardwick and Polster, 2002) .
The importance of lipids in the mechanisms of cytochrome release has recently been further highlighted. Cardiolipin is an acidic phospholipid that is found uniquely in the mitochondria and is localized to Figure 1 Changes in membrane curvature. Lipids within membranes may change the membrane curvature by virtue of the relative sizes of the acyl chains and head groups, and in turn proteins may compensate for this. Bid transports lipids to the OMM and promotes a negative curvature of membranes. CsA has been shown to promote positive membrane curvature and can prevent tBid-induced membrane destabilization the IMM but may also be present at contact sites between the OMM and IMM. Cardiolipin binds to cytochrome c and its presence was found to be important in the Bid and Bax induced release from synthetic liposomes (Kuwana et al., 2002; Zamzami and Kroemer, 2003) . This implied that cardiolipin may be the missing factor that was implicated by previous studies, although data had proposed a protein rather than a phospholipid (Roucou et al., 2002b) .
The latest modelling of mitochondrial membrane permeability (MMP) by synthetic liposomes showed that Bax and Bid pores could be created that would release proteins of up to 2 MDa (Kuwana et al., 2002) . However, more data are emerging that the release of apoptogenic proteins in vivo is differential (Arnoult et al., 2003) at least over the time-frame studied. For example, simply permeabilizing the OMM with a detergent such as digitonin does not induce a complete release of cytochrome c (Scorrano et al., 2002) while conversely, treatment with tBid that is sufficient to induce complete release of cytochrome c from isolated mitochondria does not correspond to a complete permeabilization of the OMM. These data suggest that although a nonspecific large pore could be formed in the OMM cytochrome c must be made 'available' for release.
This hypothesis was first put forward by Ott et al., who proposed a two-step model for cytochrome c release where tBid is responsible for mobilizing the majority of cytochrome c that is bound to cardiolipin (Ott et al., 2002) . In addition, tBid induces a severe remodelling of the cristae of isolated mitochondria (Scorrano et al., 2002) , and that this defined a separate function of tBid which could be suppressed by the PTP inhibitor CsA, and disassociated from the release of cytochrome c (reviewed in Reed and Green, 2002) . A number of other agents (e.g. thapsigargin, tunicamycin, brefeldin A and heat shock) have since been found to promote the reorganization of cristae in the absence of Bak and Bax and perhaps prime the mitochondria for the release of proteins. How this reorganization of mitochondrial cristae happens remains unknown but could involve mechanisms that usually govern mitochondrial morphology.
Morphological changes
Alterations in the cristae of mitochondria are known to occur following mutations in genes governing mitochondrial morphology. Mitochondria often form a continuous network within the cell, rather than the isolated organelles that are present following mitochondrial isolation. The dynamic network is constantly undergoing fusion and fission events in a healthy cell, but apoptotic inducers such as staurosporine or etoposide induce a fragmentation of the network that could contribute to an increase or deregulation of fission events. Mammalian mitochondrial fission involves hFis1 an integral OMM protein (James et al., 2003) and Drp1, a dynamin-like GTPase that might function to constrict the OMM at specific sites (Smirnova et al., 1998).
Frank et al. first explored the link between mammalian mitochondrial morphology and apoptosis and showed that inhibition of fission by a dominant-negative form of Drp1 not only inhibited fragmentation induced by Bax or staurosporine but also reduced cytochrome c release (Frank et al., 2001) . Interestingly, staurosporine (STS) promotes the appearance of clusters of Bak or Bax molecules at the OMM (Nechushtan et al., 2001) , and after STS treatment, Bax colocalized with Drp1 and a protein involved in mitochondrial fusion, Mfn2 (Karbowski et al., 2002) at specific sites on the OMM. Moreover, overexpression of hFis1 promotes mitochondrial fragmentation of mitochondria and release of cytochrome c (James et al., 2003) .
Therefore, the mitochondrial location of Bax and Bak could reflect association with and even participation in the integral processes of membrane fission and fusion that determine the plasticity and dynamics of mitochondria within a cell.
Mitochondrial fragmentation and subsequent aggregation are not affected by expression of the antiapoptotic protein Bcl-xL, although Bcl-xL does prevent cytochrome c release (Haga et al., 2003; James et al., 2003) . These data provide another level of complexity in the permeabilization of the OMM and suggest that proapoptotic Bcl-2 family members may 'hijack' the mechanics of mitochondrial fission in order to facilitate cytochrome c release (reviewed in Karbowski and Youle, 2003) . There is also the suggestion that fragmented mitochondria remodel the cristae compartment and therefore these are able to release more cytochrome c than normal mitochondria in response to an apoptotic signal (Scorrano, 2003) .
Reactive oxygen species
Another source of modification of the OMM and or release of cytochrome c could derive from nitric oxide (NO), a highly diffusible gas which is synthesized by constitutively expressed or inducible NO synthases. Aside from its role in vascular tone and cellular defense NO can inhibit respiration by binding to cytochrome c oxidase and results in dissipation of the DC m , and a depletion of ATP which also favours formation of superoxide anions (reviewed in Moncada and Erusalimsky, 2002) . Cell death induced by NO may be subverted if the cell is able to invoke anaerobic glycolysis, which prevents the further depletion of ATP and restores the DC m . Superoxide anions (O 2 À ) can either be broken down by the mitochondrial enzyme superoxide dismutase (SOD) to form hydrogen peroxide (H 2 O 2 ) or lead to the formation of peroxynitrite (ONOO À ). These oxidants are normally broken down by mitochondrial glutathione or thiol-containing compounds. However, sustained exposure to high levels may deplete the protective pool of glutathione and render the mitochondrial environment more sensitive to oxidative stress leading to changes in membrane proteins such as ANT or modification (e.g. nitration) of apoptogenic proteins (Cassina et al., 2000) . Therefore, NO may well be a cofactor in regulating the modification of proteins in the mitochondria. In addition, NO induces gene transcription and this provides a further possibility for modification of the OMM by nuclear encoded proteins. Taken together ROS, and the resulting cellular redox change, can play an integral part in signal transduction during apoptosis (Kannan and Jain, 2000) .
Role of calcium
The involvement of the classical PTP in drug-induced apoptosis has already been discussed but Ca 2 þ may still play a role in influencing OMM permeability. Mitochondria act as a buffer for calcium levels in the cell, with decreases in calcium in the endoplasmic reticulum (ER) dampened by a corresponding increase in the mitochondria. Apoptotic agents such as staurosporine, doxorubicin and ceramide can promote the release of Ca 2 þ from the ER and its subsequent accumulation in the mitochondria, events that occurs several hours before the release of cytochrome c (Nutt et al., 2002) . These increases may be mediated by activated ER proteins, for example, the p20 cleaved product of BAP31 (Breckenridge et al., 2003) or by tBid which enhances transfer of IP3 mediated Ca 2 þ signals to mitochondria (Csordas et al., 2002) .
The increases in mitochondrial Ca 2 þ have been linked to the recruitment of Drp1, perhaps preparing the mitochondria for fragmentation (Breckenridge et al., 2003) . Changes in calcium levels appear to be regulated by both pro-and antiapoptotic members of the Bcl-2 family. Bcl-2 expression decreases free Ca 2 þ in the ER (Foyouzi-Youssefi et al., 2000) and Bax, a proportion of which is localized to the ER, mediates the release of calcium in the ER that is induced by staurosporine (Nutt et al., 2002) .
In addition to sensitizing mitochondria to injury, Ca 2 þ may also provide a signalling mechanism whereby an apoptotic signal can be transmitted to all the mitochondria within the cell ). This has the advantage of providing fidelity within a single cell of the apoptotic signal otherwise all mitochondria would have to be signalled individually. This also concurs with the finding that the release of cytochrome c involves the whole population of mitochondria within cells, although in HeLa cells the propagation a wave of cytochrome c release was not observed (Goldstein et al., 2000) . However, it is thought that a high mitochondrial density such as that found in cardiac myotubes could facilitate the formation of this wave. Interestingly, in myotubes where waves of Ca 2 þ release are seen in the sarcoplasmic reticulum, treatment with ceramide provokes a second calcium wave from the mitochondria and it is this wave that correlates to mitochondrial depolarization and cytochrome c release (reviewed in Hajnoczky et al., 2001 ). Despite the above observations, it can still be argued that mitochondria are morphologically heterogeneous entities and not luminally connected (Collins et al., 2002) .
Mechanisms of resistance
Bcl-2 is capable of prolonging cell survival by inhibiting apoptotic cell death (Hengartner and Horvitz, 1994) and the discovery that follicular lymphomas overexpressed the antiapoptotic Bcl-2 strongly suggested that malignancy and disruption of the apoptotic pathway are linked (Tsujimoto et al., 1984; Vaux, 1998) . Therefore, for a cell to become cancerous it must somehow escape the apoptotic pathway (Igney and Krammer, 2002) . One means of escaping the apoptotic pathway would be to regulate, directly or indirectly, the permeabilization of the OMM. The following mechanisms highlight just a few of the many strategies employed by cells that pursue the path to neoplastic transformation.
Oncogenes such as c-myc paradoxically can increase a cell's sensitivity to apoptotic stimuli while increasing the proliferation rate. Recently, it has been shown that cmyc expression induces the permeabilization of the mitochondrial membrane, and that the activity for permeabilization was found in a cytosolic fraction that coeluted with full-length Bid (Iaccarino et al., 2003) . Although it has been reported that Bid is not requisite for c-Myc killing (Juin et al., 2002) Bax is required, as double knockout cells that had been transfected with Bax had a restored sensitivity to apoptosis without affecting the levels, conformation or localization of Bax (Juin et al., 2002) . Interestingly, c-Myc also upregulates cyclophilin D and VDAC and the benzodiazapine receptor, all components of the permeability transition pore (Iaccarino et al., 2003) , and cells that overexpress VDAC are known to be more sensitive to apoptosis (Rapizzi et al., 2002) , perhaps by providing a secondary method of OMM permeability.
Regulation of PTP components is also implicated in resistance strategies. Hexokinase (HK) I and II play important roles in cancer by improving the cells energy supply and protecting against cell death (Bryson et al., 2002; Pastorino et al., 2002) , and the mitochondrially bound forms of HK are elevated in many tumour cells (Azoulay-Zohar et al., 2004) . HK1 is able to protect against STS induced cell death of leukaemic cells and binds directly to VDAC (Azoulay-Zohar et al., 2004) . While this binding is reported to inhibit the PTP, it may also affect proposed VDAC-Bax-mediated pores in the OMM.
Similarly, an alteration of the redox environment of the mitochondria also appears to be linked to resistance to apoptotic signals. Cell lines that are resistant to some anticancer drugs display mitochondria that contain higher amounts of glutathione and increased number of cristae and intramitochondrial matrix granules (Dvorakova et al., 2002) . In addition, expression of glutathione-S-transferase PI-1 is known to correlate to resistance by cancer cells to therapy (Duvoix et al., 2003) . The increased amounts of glutathione may serve to negate the effect of increased ROS that can be induced by chemotherapy.
Tumour cells are often deficient in DNA damage response pathways. Central to this response is p53, a gene commonly mutated in human cancers. Wild-type p53 induces transcription of p21, Bax, Mdm2, gadd45, Killer/DR5 and hence a loss of p53 expression and/or function is a feature of many tumour cells (see El-Deiry, 2003 for recent review). In addition to its known role of upregulating PUMA (Nakano and Vousden, 2001 ) and NoxA (Oda et al., 2000) , p53 has recently been reported to regulate the expression of Bid, as Bid mRNA is increased in a p53-dependent manner particularly in colonic epithelium (Sax et al., 2002) . This indicates that loss of p53 wild-type function reduces the cells ability to activate BH3-only proteins in response to apoptotic signals although an additional coordinated increase in cell proliferation provides a more potent environment for rapid malignancy (reviewed in Kaufmann and Vaux, 2003) .
Inhibition of the proapoptotic proteins Bax and/or Bak could be useful strategy to promote survival of cancer cells, as antiapoptotic proteins would then be in abundance. Studies of cells taken from malignant tissues have already shown that the Bax gene may well undergo multiple mutations (Catasus et al., 2000; Inoue et al., 2000) . Inhibition of Bax and prevention of its mitochondrial relocalization has also recently been demonstrated. Ku70 : Ku80 and DNA-PKcs are essential for DNA repair by nonhomologous end-joining-NHEJ (reviewed by Karran, 2000) . Overexpression of Ku70 suppresses Bax-mediated apoptosis as Ku70 binds to the Nterminus of Bax and prevents Bax translocation to mitochondria. It also reduced STS-induced apoptosis and cytochrome c release in HeLa cells and UVC apoptosis in HEK293T cells. Ku may also be involved in the modulation of heat-shock gene expression as decreased levels of Ku following treatment with anticancer drugs correlated with increased levels of Hsp75 (localized to mitochondria) and downregulation of Hsp70 (Kim et al., 1999) . Abrogation of Hsp70 has been shown to induce apoptosis (Wei et al., 1995) and conversely increased levels of Hsp70 have been linked to protection from apoptosis due to its interactions with AIF (Gurbuxani et al., 2003) and Apaf-1 (Saleh et al., 2000) therefore suggesting that Ku may mediate resistance to apoptosis in multiple ways.
Therapeutic regimens
The above examples (see also Table 1) illustrate that deregulated apoptosis is a fundamental aspect of tumour biology. Defects in the execution of the apoptotic programme enable neoplastic cells to survive beyond their intended lifespans, allowing them time to accumulative genetic alterations that deregulate cell proliferation, increase cell motility and other changes that play an important role in tumour pathogenesis (Reed, 1999) .
Virtually, all known cytotoxic anticancer drugs currently in clinical use, when effective, induce apoptosis of malignant cells. Cancer-associated defects in apoptosis also play a role in chemoresistance and radioresistance increasing the threshold for cell death and thereby requiring higher doses for tumour killing (Makin and Hickman, 2000) . Unraveling the pathways leading to MMP has already offered new targets for gene therapy and drug discovery with a new class of targeted therapeutics emerging from the deeper understanding of the molecular mechanisms that underlie apoptosis.
The Bcl-2 family proteins are the central regulators of the intrinsic pathways that either suppress or promote changes in mitochondrial membrane permeability and overexpression of antiapoptotic Bcl-2 or Bcl-xL occurs in more than half of all tumours (Amundson et al., 2000) rendering those tumour cells resistant to myriad apoptotic stimuli and most cytotoxic anticancer drugs. Strategies being employed to overcome these cytoprotective effects include attacking the proteins with small molecule drugs, inducing mRNA degradation with antisense oligonucleotides or silencing gene transcription.
Several groups have presented preclinical data regarding BH3-mimetic compounds (Bcl-2/Bcl-xL antagonists) that occupy the BH3 binding site on Bcl-2 or Bcl-xL, abrogating their cytoprotective functions (Letai et al., 2002) . Alternatively it may be possible to activate Bak or Bax using drugs that mimic agonist BH3 peptides (Letai et al., 2002) . Other strategies for countering Bcl-2 and Bcl-xL in cancer include expression of opposing proapoptotic family members such as Bax with p53 adenovirus (in Phase III trials) or with Mda7 (IL 24) adenovirus gene therapy (completed Phase I trials). Similarly, adenoviral transfer of full-length Bid increased apoptosis of nonsmall cell lung cancer cell lines (Fukazawa et al., 2003) .
Combination therapies that employ downregulation of the antiapoptotic proteins as a means of sensitizing cells has also proved effective. Reduction of Bcl-xL protein levels by 50% using antisense oligonucleotides, in Caco2 colon cancer cells increased sensitivity to ionizing radiation or cisplatin by 300% (Wacheck et al., 2003) . Overexpression of Bcl-2 in human pancreatic cancer cells not only protected from apoptosis but increased PKB levels and NFkB levels (Mortenson et al., 2003) . Selective inhibitors of Akt/PKB lower sensitivity threshold to chemotherapeutic drugs probably by downregulating IAPs and reducing Bad phosphorylation. These Akt/PKB inhibitors proved useful with K562 blast crisis cells but not with MOLT-4 leukaemic cells (Martelli et al., 2003) .
Finally, an antisense oligonucleotide (Genasense) designed to downregulate the expression of Bcl-2 is in Mitochondrial membrane permeabilization J Henry-Mowatt et al clinical trials and has been shown to be particularly effective in downregulating Bcl-2 in lymphoma cells and trials are now examining the efficacy of Genasense as a single agent in melanoma, prostate, breast and colon cancers (Banerjee, 2001) . Proteosome inhibitors such as lactacystin or MG132 have been successfully used against chemotherapy resistant cell lines (Dewson et al., 2003) . They somehow generate a conformational change in Bax (without affecting Bid or Bax levels). This is followed translocation of Bax to the outer mitochondrial membrane, loss of MMP and cytochrome c release.
Compounds that inhibit histone deacetylases may also favourably modulate the expression of Bcl-2 and Bcl-xL in some tumour cell lines (Reed, 2002) because HDAC inhibitors are known to promote apoptosis and are now being tested as a new class of anticancer drug. One such drug MS-275 promotes apoptosis through an increase in ROS and the release of cytochrome c, all of which can be prevented by application of free radical scavengers (Rosato et al., 2003) . This HDAC inhibitor is also more potent if p21 (WAF1) is downregulated by antisense (Rosato et al., 2003) . Apicidin used against Bcr-Abl positive leukaemic cells is a HDAC inhibitor and promotes apoptosis and downregulation of p210-BcrAbl in a caspase-dependent manner (Cheong et al., 2003) . Bcr-Abl associates with p85 of PI3K and increases the activity of PI3K but this association is not required for cell death. Therefore, blocking it might also deactivate growth responses of these cells (Amarante-Mendes et al., 1997) . SBHA is yet another HDAC inhibitor that induces apoptosis in melanoma cell lines in a mitochondrial and caspase-dependent manner by regulating Bcl-2 family members and caspases. It upregulates caspase-8, Bid, Bak, Bax and Bim and downregulates Bcl-xL and XIAP and sensitized melanoma cell lines to TRAIL-induced apoptosis (Zhang et al., 2003b) . Unfortunately, many tumour cell lines display intrinsic resistance to TRAIL, despite expressing the necessary cell-surface receptors. Pretreatment of TRAIL-resistant cell lines with a range of chemotherapeutic drugs that upregulated death receptors or caspases resulted in a high efficacy of killing in breast cancer cells (Singh et al., 2003) .
In spite of their overall importance, the Bcl-2 family members are not the only possible therapeutic targets that could influence the apoptotic pathway in cancer cells and several agents are used to initiate apoptosis in cancer cells. For example, a diverse array of agents has been successfully used to influence ROS production in cells. Retinoids such as Fenretinide or SHetA2 promote apoptosis in cancer cell lines via increased ROS (Boya et al., 2003; Chun et al., 2003) . The downstream effects of ROS production include conformational changes in Bax and Bak (Boya et al., 2003) , which subsequently lead to permeabilization of the OMM and cytochrome c release. Other reagents such as alpha-hederin which have been successfully used on lung carcinomas increase ROS via a depletion of intracellular glutathione (Swamy and Huat, 2003) while Cinnamaldehyde, an oxidant, has been shown to inhibit tumour cell proliferation possibly via the production of ROS and ultimately leads to cytochrome c release (Ka et al., 2003) .
Downstream of mitochondrial membrane permeabilization, the intrinsic and extrinsic pathways converge on downstream effector caspases. Mechanisms for suppressing apoptosis at this distal step have now been explored and their relevance to cancer is becoming progressively clear. In this regard, the inhibitor of apoptosis proteins (IAPs) function as endogenous inhibitors of caspase activation (Deveraux et al., 2001) . Overexpression of IAPs occur in many cancer cell lines and antisense-mediated reductions in IAP family members such as XIAP, cIAP1 and survivin can induce apoptosis in tumour cells in culture, or sensitize ovarian cancer cells to cytotoxic anticancer drugs like cisplatin in vitro (Li et al., 2001a) . XIAP is the most potent of the antiapoptotic IAPs. As it inhibits effector caspases such as caspase-3, it effectively blocks apoptosis triggered by the mitochondrial (intrinsic) pathway as well as that occurring via death receptor signalling (the extrinsic pathway). This suggests that XIAP would be an efficient inhibitor of apoptosis with a broader activity than Bcl-2 and it is overexpressed/deregulated in many tumours (Tamm et al., 2000; Wagenknecht et al., 2000) . An antisense to XIAP has been demonstrated to produce a significant decrease in XIAP protein expression in human xenografts during preclinical evaluation (Hu et al., 2003) .
Endogenous inhibitors and antagonists keep IAPs in check and promote apoptosis. Two of these, SMAC/ Diablo (inhibitor) and Omi/HtrA2 (antagonist) are released from the mitochondria into the cytosol during apoptosis (Du et al., 2000; Suzuki et al., 2001; Reed, 2002) . Thus, after an apoptotic stimulus, SMAC/Diablo is released from the mitochondria and displaces the IAP from its binding site on caspases to promote apoptosis. Synthetic peptides that mimic SMAC/Diablo trigger apoptosis in cultured cells treated with a wide variety of cytotoxins (Arnt et al., 2002; Guo et al., 2002; Yang et al., 2003) and significantly, the same approach enhances the antineoplastic effects of TRAIL in a brain tumour model in vivo (Fulda et al., 2002) .
Other signalling proteins have also emerged as potential drug targets based on an ability to modulate expression or function of other apoptosis regulating proteins (see Debatin et al., 2002 for recent review). For example, NFkB is activated by a plethora of signals, including death receptors and redox stress, and its hyperactivity in certain tumours has been reported (Karin et al., 2002) . Mitochondria can participate in NFkB activation by releasing an IkB/NFkB complex from the intermembrane space (Bottero et al., 2001) . The NFkB family transcription factors can induce expression of Bcl-xL (intrinsic), FLIP (extrinsic) and cIAP (convergence) pathways in some tumour cells (Karin et al., 2002) . More significantly, chemotherapy can increase expression of NFkB and it is this elevated NFkB that is implicated in resistance of cancer cells. When this induced NFkB is inhibited it enhances the apoptotic response and therefore could be used as an adjunct to chemotherapy (Cusack, 2003) . Consequently, agents that inhibit the action of NFkB are currently being pursued.
The selective screenings for drugs that target the apoptotic pathway (summarized in Table 2 ) will unavoidably, miss compounds that kill by other means. Thus in spite of advances made, it is clear that research needs to continue into the underlying signalling pathways that will result in new strategies that will target upstream and downstream mechanisms of resistance invariably present in tumour cells. These resistance mechanisms include drug-type-specific mechanisms such as reduced drug uptake, increased drug inactivation and increased repair of induced damage that serve to limit therapeutic effects in these cells.
Since most tumour cells have accumulated various defects in their apoptotic and other physiological pathways these cells should, theoretically, be more poised for cell death. Hence, methods that aim to increase prodrug activation in tumour cells can present one means of increasing the efficacy and therapeutic index of chemotherapy within those cells. For instance, DT-diaphorase is an obligate two-electron reductase that reduces quinones to hydroquinones. With certain quinone anticancer drugs, this two-electron reduction can lead to a more biologically reactive species that can crosslink DNA. RH1 is a novel DNA crosslinking agent that is activated by bioreduction, making an efficient substrate for DT-diaphorase. RH1 is rapidly taken up into cells, initiating crosslinking as it does. RH1 has now entered into Phase I/II clinical trials (CRUK/NCI) and it hoped that it might prove effective in tumours, for example, ovarian and nonsmall cell lung cancers, known to express high levels of DT-diaphorase.
Concluding remarks
The downstream inhibition of released mitochondrial factors has often been employed by cancer cells as part of a resistance strategy. However, permeabilization of the OMM remains an important step in the apoptotic cascade and some of the factors involved are schematically illustrated in Figure 2 . A definitive model for the release of apoptogenic factors is still out of reach and may involve a sequential release of proteins, through a very specific pore or modulation of a pore to allow differential release of proteins. Binding of protein and/ or lipid factors to the OMM may well regulate the creation of this pore by facilitating the environment for its creation, and subverting processes such as mitochondrial fission and fusion may also be involved. Alternatively components of the OMM modify the redox environment within the mitochondria which may in turn regulate the ability of new cytosolic translocates (e.g. Bax) to form an OMM pore.
MMP does not necessarily result in an irreversible mitochondrial dysfunction and cell death. Bax/Bak activation only initially elicits outer membrane permeability but leaves protein import function, inner membrane energy production and ultrastructure intact (Von Ahsen et al., 2000b) . Thus, positive feedback CsA negatively affects PKB/Akt-mediated survival signalling, leading to increased levels of 'active' dephosphorylated BH-3 only protein Bad and/or increase p53-dependent BH-3 only proteins (PUMA/Noxa), thereby reducing the protective effect of Bcl-2/BclxL. Import of glutathione (GSH) can be affected by lipids (LP) in the OMM (e.g. cholesterol) and Bid can induce changes in the lipidic content of the OMM. A reduction of mitochondrial GSH leads to an increase in mitochondrial reactive oxygen species (ROS) and a dissipation of DC m . Bid and its cleaved form (cut Bid) promote oligomerization of Bax and/or Bak and induces cristae remodelling (CRM). Cristae remodelling can also be induced by mitochondrial fission proteins (e.g. hFis1) which have been shown to colocalize with Bax at sites of mitochondrial membrane division. Bax binding proteins (BBP) such as Ku70 and PKCepsilon can prevent conformational changes in Bax in contrast to ROS that promotes these changes. SMAC/Diablo (red squares) and cytochrome c (red circles) exit the mitochondria possibly through a pore involving Bak or Bax, but full release of cytochrome c appears to be dependent on its release from the mitochondrial lipid cardiolipin (CL) and is influenced by ROS Mitochondrial membrane permeabilization J Henry-Mowatt et al mechanisms involving ROS or Ca 2 þ may be required for irreversible mitochondrial damage and death to occur. As cancer cells appear to have developed multiple resistance strategies, then the battle at the OMM may similarly need to be targeted towards multiple sites. So, the search for those targets continues and for all those involved it's 'once more unto the breach, dear friends' (Shakespeare, Henry V).
